News

With the completion of the deal, Perrigo now has rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. The deal also includes Novartis’s

Derived from the cell wall fractionation of non-pathogenic bacteria, MCNA is a biologic therapy developed to provide high risk non-muscle invasive bladder cancer patients who are refractory to

According to the company, MRX-I is claimed to offer physicians and patients a safer and better tolerated therapeutic option compared to the currently available oxazolidinone agents. MicuRx Pharmaceuticals

QIMR is focused on research of cancer, infectious diseases, mental health and a range of complex disorders. As part of the deal, BMS will be solely responsible for

STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients (APIs) and GMP intermediates for branded commercial drugs from regulatory

Earlier this year Symbiomix announced positive results from the first pivotal trial for SYM-1219. Symbiomix expects to finish this second pivotal trial by the end of 2015, which

The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield™ as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

Sendai virus enables delivery of genes into a host cell without permanently altering the cell’s chromosome, which is critical for stem cell therapies. Professor Shinya Yamanaka, MD, Ph.D.,

As part of the deal, R-Tech Ueno will receive $54m in cash and 2.5 million Sucampo shares and Sucampo will buy 56% of the outstanding shares of R-Tech